Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinically, we observed a significant inverse correlation between FOXO3a and FOXM1/SOX2/DNMT1 expression levels, and loss of FOXO3a expression or increased expression of FOXM1, SOX2, and DNMT1 predicted poor prognosis in breast cancer.
|
31296961 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate the expression of methylation-related proteins (5-meC and DNMT1) in the metastatic breast cancers of variable sites and its association with clinicopathologic factors.
|
28253728 |
2019 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, our data indicate that reduced DNMT1 expression along with promoter hypomethylation and increased expression of the HRR genes might have importance in chemotolerance in BC.
|
30178275 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings shed light on the mechanism of SALL2 in regulation of ER and represent a potential clinical signature that can be used to categorize breast cancer patients who may benefit from co-therapy with tamoxifen and DNMT inhibitor.
|
31657150 |
2019 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Signal transducer and activator of transcription 3 (STAT3), frequently overexpressed and activated in paclitaxel (PTX)-resistant breast cancer, promotes the expression of DNA methyltransferase one (DNMT1) to epigenetically suppress the transcription of tumor suppressor Aplasia Ras homolog one (ARHI) which can sequester STAT3 in the cytoplasm to block PTX resistance.
|
31077613 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
DNMT1 inhibitors, ChIP, CoIP, IHC and ERα inhibitors were used to explore the molecular mechanism of OCT4 in breast cancer.
|
31012189 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present data demonstrate the critical function of DNMT1 in breast cancer-related sustained activation of breast stromal fibroblasts.
|
29416775 |
2018 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ectopic circ-Dnmt1 increased the proliferative and survival capacities of breast cancer cells by stimulating cellular autophagy.
|
29973691 |
2018 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The DNA methyltransferase 1 inhibitor, 5-Aza-2'-deoxycytidine (5-Aza-dC) is a potential treatment for breast cancer.
|
30002602 |
2018 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our data reveal that Kindlin-2 promotes breast cancer development by enhancing the stability of DNMT1.
|
30287284 |
2018 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Long non-coding RNA H19 promotes the proliferation and invasion of breast cancer through upregulating DNMT1 expression by sponging miR-152.
|
28544374 |
2017 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of the current pilot study suggest the promise of AIM-FBCR in reducing FCR in survivors of breast cancer.
|
28055119 |
2017 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Physcion 8-O-β-glucopyranoside suppresses the metastasis of breast cancer in vitro and in vivo by modulating DNMT1.
|
27768961 |
2017 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
CTD_human |
In conclusion, H19 promoted proliferation and invasion of breast cancer through the miR-152/DNMT1 axis, providing a novel mechanism about the occurrence and development of breast cancer.
|
28544374 |
2017 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
DNMT1 was highly expressed in TNBC and in breast cancer with inflammatory stromal type.
|
27071379 |
2016 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mechanistically, PHF20L1 might participate in regulating DNA methylation by stabilizing DNA methyltransferase 1 (DNMT1) protein in breast cancer.
|
26588862 |
2016 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our findings also showed that knockdown of EZH2 increased RASSF2A expression in the human breast cancer cell line MCF-7 in cooperation with DNMT1.
|
27436059 |
2016 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Consistently, the expression level of DNMT1 was positively correlated with ERα in 78 breast cancer tissue samples shown by our immunohistochemistry (IHC) analysis and negatively correlated with relapse-free survival (RFS) and distance metastasis-free survival (DMFS) of ERα-positive breast cancer patients.
|
26980709 |
2016 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our studies suggest that breast CSCs are intrinsically sensitive to genetic and epigenetic modifications and can therefore be significantly affected by epigenetic-based therapies, warranting further investigation of combined DNMT and HDAC inhibition in refractory or drug-resistant breast cancer.
|
27197203 |
2016 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression of DNMT3A/B increased at the initial stages of oncogenesis and the expression of DNMT1 and HAT1 decreased at the advanced stages of breast cancer.
|
25358520 |
2015 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data indicate that (i) PLA2R1 expression in breast cancer cells is controlled by DNA methylation and histone modifications, (ii) hypermethylation of the PLA2R1 promoter region is associated with up-regulation of DNMT1, and (iii) hsa-miR-23b, -154, and -302d, as well as hsa-miR-141, -181b, and -181d-1 are potential candidates for post-transcriptional regulation of PLA2R1 expression in mammary cancer cells.
|
26672991 |
2015 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of DNMT1 or DNMT3a were associated with a significantly shorter DFS or OS in a subgroup of breast cancer patients (patients with the age ≤50 years old, ERα-negative status, or HER2-postive status).
|
24464625 |
2015 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Additionally, treatment with the DNMT inhibitor, 5-aza-deoxycytidine (DAC), synergistically increased mRNA expression of aberrantly silenced genes important in breast cancer development, including PR, RARβ, ERα, SFRP1, SFRP2, and E-cadherin in LSD2-KD cells.
|
24924415 |
2014 |
Malignant neoplasm of breast
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Basal-like breast cancers frequently express aberrant DNA hypermethylation associated with concurrent silencing of specific genes secondary to DNMT3b overexpression and DNMT hyperactivity.
|
24297604 |
2014 |
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to evaluate the frequencies of methylation of the three genomic loci encoding the miR-124a in primary breast cancers and to investigate their relationships with the clinicopathological characteristics of the tumors and with the expression levels of DNMT1, DNMT3a, and DNMT3b.
|
24375250 |
2014 |